Tech Transfer eNews Blog
Industry-Sponsored Research Management sample issue

MD Anderson and Spectrum Pharma sign licensing deal over anti-tumor drug


By Jesse Schwartz
Published: May 9th, 2018

The University of Texas MD Anderson Cancer Center has licensed out certain uses of the tumor-fighting drug poziotinib to biotech company Spectrum Pharmaceuticals.

The license agreement further solidifies and extends MD Anderson and Spectrum’s collaboration on poziotinib, which has shown to inhibit tumor activity in certain cancers.

The agreement grants Spectrum rights to filed patents related to the drug’s use in targeting exon 20 mutations – a key marker for some lung cancers – as well as any future discoveries related to the use of poziotinib that may come from the lab of lead investigator Dr. John Heymach’s lab at MD Anderson.   The newly filed patents, if granted, are expected to extend Spectrum’s IP protection for poziotinib through 2037.

“We’ve both only begun to scratch the surface of the science and poziotinib’s potential as a targeted treatment for solid tumors,” says Joe Turgeon, president and CEO of Spectrum. “We are thrilled to enter this new agreement that strengthens and potentially extends our patent protection until 2037 as we continue this journey of discovery together.”

Ferran Prat, senior vice president of research administration and industry relations at MD Anderson, comments, “We are delighted to continue our collaboration with Spectrum under this agreement, which highlights how MD Anderson allies with private sector partners to provide new options for cancer patients.”

Source: Business Wire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment